Get to know our clinical trials
Phase II study of JNJ-90301900 with chemoradiotherapy and durvalumab in non-small cell lung cancer
THE PURPOSE OF THIS STUDY IS TO EVALUATE THE INJECTION OF THE RADIATION ENHANCER JNJ-90301900 INTO THEIR CANCER PRIOR TO CONCOMITANT CHEMORADIOTHERAPY (CCRTC) FOLLOWED BY IMMUNOTHERAPY (ITC) COMPARED TO CCRT ALONE FOLLOWED BY ITC TO HELP RESEARCHERS LEARN MORE ABOUT THE POTENTIAL EFFICACY AND SAFETY OF JNJ-90301900 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (NSCLC).
Technical Summary
- RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE II STUDY WITH ACTIVE TREATMENT OF JNJ-90301900 IN COMBINATION WITH CHEMORADIOTHERAPY FOLLOWED BY DURVALUMAB IN LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER.
- Code EudraCT: 2024-511400-16
- Protocol number: 90301900NSC2001
- Promoter: Janssen-Cilag
- Molecule/Drug: JNJ-90301900
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.